Neutrophil-to-Lymphocyte Ratio Can Distinguish Cystitis From OAB
By Elana Gotkine HealthDay Reporter
MONDAY, Jan. 8, 2024 -- Serum neutrophil-to-lymphocyte ratio (NLR) can help differentiate interstitial cystitis/bladder pain syndrome (IC/BPS) from overactive bladder (OAB), according to a study published online Nov. 8 in BMC Urology.
Hanwei Ke, from Peking University People's Hospital in Beijing, and colleagues conducted a retrospective analysis involving 70 women diagnosed with IC/BPS, 20 diagnosed with OAB, and a randomly selected cohort of 150 healthy women (normal). All participants underwent a comprehensive panel of blood tests, and the NLR was determined.
The researchers observed significant differences in the NLR levels among the IC/BPS, normal, and OAB groups. Notably divergent NLR levels were demonstrated in Hunner type IC (HIC) compared with non-Hunner type IC (NHIC) within the IC/BPS group. Positive correlations were also seen between NLR and nighttime voids, the Interstitial Cystitis Problem Index, Interstitial Cystitis Symptom Index, Pelvic Pain and Urgency/Frequency questionnaire (PUF), and PUF Symptom Scale. The area under the receiver operating characteristic curve analysis for NLR was 0.765 and 0.707 for distinguishing IC/BPS from the normal group and IC from OAB, respectively, and was 0.723 for differentiating HIC and NHIC patients.
"Our study underscores the link between heightened NLR and the symptomatology and onset of IC/BPS, underscoring the potential of NLR as a diagnostic marker for IC/BPS," the authors write. "Given the ongoing diagnostic debates surrounding IC/BPS, NLR can offer valuable support in the diagnostic process."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted January 2024
Read this next
Biomarkers + Patient-Reported Outcomes Up Prediction of Interstitial Cystitis
TUESDAY, May 7, 2024 -- The integration of biomarkers and patient-reported outcomes (PROs) improves prediction of interstitial cystitis (IC)/bladder pain syndrome, according to a...
FDA Approves New Antibiotic, Pivya, for Uncomplicated Urinary Tract Infections
TUESDAY, April 30, 2024 -- The U.S. Food and Drug Administration has approved Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary tract...
Computer Prompts Could Reduce Empiric Antibiotic Use for UTI
FRIDAY, April 19, 2024 -- For non-critically ill patients with urinary tract infection (UTI), computerized provider order entry (CPOE) prompts providing patient- and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.